Media ReleasesImmutep

View All Immutep News

Immutep - Quarterly Activities/Appendix 4C Cash Flow Report

* New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmark
*  Constructive feedback from the US FDA regarding the clinical development program for efti in metastatic breast cancer (MBC)
* New interim data for 1st line NSCLC patients from TACTI-002 to be reported in a prestigious Oral Presentation at ASCO in June 2022
* Phase IIb TACTI-003 patient recruitment advancing
* Strong cash and cash equivalent balance as at 31 March 2022: $87.2 million
* Distinguished Australian businesswoman, Lucy Turnbull AO, re-joins Board as Non-executive Director (NED), following the passing of NED Grant Chamberlain

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.